MCID: THR001
MIFTS: 62

Thrombocytopenia Due to Platelet Alloimmunization

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 74
Immune Thrombocytopenia 12 77 54 26 38 15 64
Autoimmune Thrombocytopenia 26 30 56 74
Immune Thrombocytopenic Purpura 26 74
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 26
Autoimmune Thrombocytopenic Purpura 26
Auto-Immune Thrombocytopenia 12
Werlhof Disease 26
Itp 26

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
KEGG 38 H01240
NCIt 51 C3991
SNOMED-CT 69 2897005

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health : 64 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites).Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to amegakaryocytic thrombocytopenia, congenital and purpura. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and t cells, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 77 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 516)
# Related Disease Score Top Affiliating Genes
1 amegakaryocytic thrombocytopenia, congenital 32.0 MPL THPO
2 purpura 32.0 ITGA2B ITGB3 MPL THPO
3 thrombocytopenic purpura, autoimmune 31.7 FCGR2C ITGA2B ITGB3 MPL SELP THPO
4 thrombocytosis 30.3 MPL SELP THPO
5 thrombocytopenia 30.0 GP9 ITGA2 ITGA2B ITGB3 MPL THPO
6 polycythemia vera 29.9 ITGB3 MPL SELP THPO
7 essential thrombocythemia 29.7 ITGA2B ITGB3 MPL SELP THPO
8 clopidogrel resistance 29.6 ITGB3 SELP
9 bernard-soulier syndrome 29.5 GP9 ITGA2 ITGA2B ITGB3 THPO
10 blood platelet disease 28.9 GP9 ITGA2B ITGB3 MPL SELP THPO
11 thrombasthenia 28.9 GP9 ITGA2 ITGA2B ITGB3 SELP
12 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.2
13 sea-blue histiocyte disease 11.7
14 immunodeficiency, common variable, 8, with autoimmunity 11.6
15 ras-associated autoimmune leukoproliferative disorder 11.4
16 spondyloenchondrodysplasia 11.4
17 purine nucleoside phosphorylase deficiency 11.1
18 inosine triphosphatase deficiency 11.1
19 autoimmune lymphoproliferative syndrome due to ctla4 haploinsuffiency 11.1
20 antiphospholipid syndrome, familial 11.0
21 hepatitis 10.5
22 thrombotic thrombocytopenic purpura 10.4
23 helicobacter pylori infection 10.4
24 leukemia 10.4
25 lymphoma 10.4
26 myelodysplastic syndrome 10.3
27 lymphocytic leukemia 10.3
28 thrombocytopenia 3 10.3 MPL THPO
29 thrombocythemia 1 10.3 MPL THPO
30 thrombosis 10.3
31 dyskeratosis congenita, autosomal dominant 6 10.3 MPL THPO
32 bleeding disorder, platelet-type, 16 10.3 ITGA2B ITGB3
33 leukemia, acute lymphoblastic 10.3
34 hemolytic anemia 10.3
35 hepatitis c 10.3
36 antiphospholipid syndrome 10.3
37 cytomegalovirus infection 10.3
38 autosomal dominant macrothrombocytopenia 10.2 ITGA2B ITGB3
39 aspirin resistance 10.2 ITGA2 ITGB3
40 stroke, ischemic 10.2
41 aspergillosis 10.2
42 nocardiosis 10.2
43 systemic lupus erythematosus 10.2
44 myocardial infarction 10.2
45 autoimmune hepatitis 10.2
46 common variable immunodeficiency 10.2
47 ulcerative colitis 10.2
48 colitis 10.2
49 rabies 10.2
50 lupus erythematosus 10.2

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

GenomeRNAi Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CCR6 FCGR2A IL17A ITGA2 ITGA2B THPO

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CCR6 CD19 FCGR2A FCGR2B FCGRT GP9
2 homeostasis/metabolism MP:0005376 9.7 CCR6 CD19 FCGR2B FCGRT IL17A ITGA2
3 immune system MP:0005387 9.36 CCR6 CD19 FCGR2A FCGR2B FCGRT IL17A

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMedHealth treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 64

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count.Adults who have mild ITP may not need any treatment, other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated.The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura), usually are treated.Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1002)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
3
Artesunate Approved, Investigational Phase 4,Not Applicable 88495-63-0 5464098 6917864
4
Artemether Approved Phase 4,Phase 3 71963-77-4 68911 119380
5
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
6
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
7
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
8
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
9
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
13
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Polyestradiol phosphate Approved Phase 4,Phase 2 28014-46-2
16
Besifloxacin Approved Phase 4 141388-76-3
17
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
18
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
20
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
21
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
22
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
23
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
24
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
25
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
26
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
27
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
28
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
29
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
30
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
32
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 537-46-2 10836
33
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2 68-04-2
34
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
35
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
37
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
38
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
39
Hydroxychloroquine Approved Phase 4 118-42-3 3652
40
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
41
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
42
Dinoprostone Approved Phase 4 363-24-6 5280360
43
Ezetimibe Approved Phase 4 163222-33-1 150311
44
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
45
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
46
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
47
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
48
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Not Applicable 122320-73-4 77999
49
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 46507594 772
50
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 1609)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
4 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4 Low dose of alfentanil hydrochloride;Normal dose of alfentanil hydrochloride
5 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
6 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
7 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
8 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
9 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
10 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
11 Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery Unknown status NCT02085551 Phase 4
12 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
13 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
14 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
15 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
16 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
17 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
18 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
19 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
20 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
21 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
22 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
23 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
24 Treatment of Depression in Adults Completed NCT00073697 Phase 4 Escitalopram
25 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
26 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
27 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4 Ketorolac Tromethamine 0.45%;Bromfenac 0.09%
28 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
29 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
30 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
31 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
32 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4 rhGH
33 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
34 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4 ketorolac 0.4%, bromfenac 0.09%
35 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
36 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
37 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
38 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
39 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4 Raltegravir, lopinavir, ritonavir
40 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
41 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4 Imipramine
42 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
43 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
44 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
45 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
46 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4 simvastatin and ezetimibe
47 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4 escitalopram
48 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
49 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
50 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 30 FCGR2C

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

42
Testes, Kidney, T Cells, Bone Marrow, B Cells, Brain, Myeloid

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 1798)
# Title Authors Year
1
The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. ( 30609018 )
2019
2
Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. ( 29580123 )
2019
3
Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. ( 30537439 )
2019
4
A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura. ( 30840965 )
2019
5
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. ( 30880797 )
2019
6
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. ( 29357781 )
2019
7
Treatment of primary and secondary immune thrombocytopenia. ( 30920453 )
2019
8
Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. ( 30923095 )
2019
9
Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. ( 30923461 )
2019
10
Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. ( 30933417 )
2019
11
High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia. ( 30936868 )
2019
12
Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia. ( 30944836 )
2019
13
Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. ( 30945320 )
2019
14
Disseminated tuberculosis with severe immune thrombocytopenia. ( 30949428 )
2019
15
Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. ( 30950041 )
2019
16
Diagnosis and management of primary immune thrombocytopenia in adults. ( 30951423 )
2019
17
Fostamatinib for the treatment of immune thrombocytopenia in adults. ( 30951590 )
2019
18
Involvement of Interferon-γ + 874A/T Polymorphism in the Pathogenesis of and Therapeutic Response to Immune Thrombocytopenia. ( 30955035 )
2019
19
A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag. ( 30956967 )
2019
20
Antigenic Mimicry in Paraneoplastic Immune Thrombocytopenia. ( 30967864 )
2019
21
Immune Thrombocytopenia is Still the Commonest Diagnosis on Consultative Hematology. ( 30988575 )
2019
22
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. ( 31007886 )
2019
23
Platelet and peripheral white blood cell counts at diagnosis predict the response of adult immune thrombocytopenia to recombinant human interleukin-11: A retrospective, single-center, case-control study. ( 31008943 )
2019
24
Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. ( 31012979 )
2019
25
Indirubin regulates MPL and TNF expression in peripheral blood mononuclear cells from patients with primary immune thrombocytopenia. ( 31014934 )
2019
26
Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts. ( 31026663 )
2019
27
Investigation of Dynamic Thiol/Disulfide Homeostasis in Children With Acute Immune Thrombocytopenia. ( 31033791 )
2019
28
The Procoagulant Profile in Patients with Immune Thrombocytopenia and Its Association with Bleeding Symptoms. ( 31041793 )
2019
29
Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag. ( 31049228 )
2019
30
Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. ( 31053569 )
2019
31
Familial Immune Thrombocytopenia Associated With a Novel Variant in IKZF1. ( 31069201 )
2019
32
Blockade of T-cell immunoglobulin and mucin domain-containing molecule 3 aggravates T-helper cell 1 polarization in immune thrombocytopenia. ( 31090595 )
2019
33
Immune thrombocytopenia associated with Helicobacter pylori - unclear associative mechanisms. ( 31101516 )
2019
34
Appropriateness of intravenous immunoglobulin use in immune thrombocytopenia (ITP): A Canadian centre deep dive audit. ( 31105060 )
2019
35
A rare case of immune thrombocytopenia secondary to breast cancer. ( 30656035 )
2019
36
Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. ( 30661482 )
2019
37
Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. ( 30663792 )
2019
38
All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-IL-1β loop. ( 30679324 )
2019
39
A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report. ( 30686269 )
2019
40
Efficacy and safety of a new intravenous immunoglobulin (Panzyga® ) in chronic immune thrombocytopenia. ( 30687970 )
2019
41
Long-Term Fostamatinib Treatment of Adults with Immune Thrombocytopenia (ITP) during the Phase 3 Clinical Trial Program. ( 30784097 )
2019
42
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. ( 30785358 )
2019
43
Associations between FCGR polymorphisms and immune thrombocytopenia: a meta-analysis. ( 30786049 )
2019
44
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. ( 30793285 )
2019
45
Avatrombopag for the treatment of immune thrombocytopenia. ( 30799645 )
2019
46
The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. ( 30801909 )
2019
47
Aberrant expression of NLRP3, NLRC4 and NLRP6 inflammasomes in patients with primary immune thrombocytopenia. ( 30802690 )
2019
48
Fostamatinib for the treatment of chronic immune thrombocytopenia. ( 30803989 )
2019
49
Change Theory Contributes to Choosing Wisely for Immune Thrombocytopenia. ( 30808652 )
2019
50
Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicenter study. ( 30816621 )
2019

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to KEGG:

38
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 CCR6 IL17A ITGA2 ITGA2B ITGB3 THPO
2
Show member pathways
13.16 GP9 ITGA2 ITGA2B ITGB3 MPL SELP
3
Show member pathways
12.93 FCGR2A FCGR2B ITGA2 ITGA2B ITGB3 THPO
4
Show member pathways
12.24 ITGA2 ITGA2B ITGB3 THPO
5 12.08 FCGR2A FCGR2B FCGR2C
6
Show member pathways
12.06 ITGA2 ITGA2B ITGB3
7
Show member pathways
12.01 GP9 ITGA2 ITGA2B ITGB3
8 11.98 ITGA2 ITGA2B ITGB3
9 11.95 FCGR2A FCGR2B FCGR2C ITGA2 ITGB3
10
Show member pathways
11.89 FCGR2A FCGR2B FCGR2C
11 11.89 FCGR2A FCGR2B FCGR2C ITGB3
12
Show member pathways
11.88 ITGA2 ITGA2B ITGB3
13 11.86 FCGR2A FCGR2C SELP
14 11.81 FCGR2A GP9 ITGA2 ITGA2B ITGB3
15 11.8 CD19 ITGA2 ITGA2B ITGB3
16 11.69 FCGR2A ITGA2 ITGA2B ITGB3
17
Show member pathways
11.65 GP9 ITGA2B ITGB3 MPL THPO
18 11.58 ITGA2 ITGA2B ITGB3 THPO
19 11.57 FCGR2A FCGR2B FCGR2C SELP
20 11.51 ITGA2 ITGA2B ITGB3
21 11.49 CD19 ITGA2 ITGA2B ITGB3
22 11.44 FCGR2A ITGA2B ITGB3
23 11.42 CD19 GP9 ITGA2 ITGA2B ITGB3 THPO
24 11.41 GP9 ITGA2 ITGA2B ITGB3
25 11.4 GP9 ITGA2B ITGB3
26 11.4 FCGR2A FCGR2B FCGR2C IL17A ITGB3
27 11.37 ITGA2 ITGA2B ITGB3
28 11.23 CD19 FCGR2A ITGA2 ITGA2B ITGB3 MPL
29 11.19 ITGA2B ITGB3
30 11.06 ITGA2B ITGB3
31 10.94 ITGA2B ITGB3
32 10.88 IL17A ITGA2 ITGA2B ITGB3 THPO
33 10.71 GP9 ITGA2

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CCR6 CD19 FCGR2B GP9 ITGB3 MPL
2 cell surface GO:0009986 9.8 CCR6 ITGA2 ITGA2B ITGB3 MPL
3 integrin complex GO:0008305 9.33 ITGA2 ITGA2B ITGB3
4 external side of plasma membrane GO:0009897 9.17 CCR6 CD19 FCGR2B IL17A ITGA2 ITGA2B
5 platelet alpha granule membrane GO:0031092 9.13 ITGA2B ITGB3 SELP
6 integral component of membrane GO:0016021 10.1 CCR6 CD19 FCGR2A FCGR2B FCGR2C FCGRT
7 plasma membrane GO:0005886 10.03 CCR6 CD19 FCGR2A FCGR2B FCGR2C FCGRT

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.72 GP9 ITGA2 ITGA2B ITGB3 SELP
2 blood coagulation GO:0007596 9.69 GP9 ITGA2 ITGB3
3 immune response GO:0006955 9.65 CCR6 FCGR2B FCGR2C FCGRT IL17A
4 platelet degranulation GO:0002576 9.63 ITGA2B ITGB3 SELP
5 cell-matrix adhesion GO:0007160 9.58 ITGA2 ITGA2B ITGB3
6 integrin-mediated signaling pathway GO:0007229 9.54 ITGA2 ITGA2B ITGB3
7 cell adhesion mediated by integrin GO:0033627 9.49 ITGA2 ITGB3
8 cell-substrate adhesion GO:0031589 9.48 ITGA2 ITGB3
9 mesodermal cell differentiation GO:0048333 9.43 ITGA2 ITGB3
10 thrombopoietin-mediated signaling pathway GO:0038163 9.16 MPL THPO
11 platelet aggregation GO:0070527 9.13 ITGA2B ITGB3 MPL
12 positive regulation of leukocyte migration GO:0002687 8.8 ITGA2 ITGA2B SELP

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix binding GO:0050840 9.16 ITGA2B ITGB3
2 fibrinogen binding GO:0070051 8.96 ITGA2B ITGB3
3 IgG binding GO:0019864 8.92 FCGR2A FCGR2B FCGR2C FCGRT

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....